This group comprises preparations used in the treatment of malignant neoplastic diseases, and immunomodulating agents.
Corticosteroids for systemic use, see H02.
Immunosuppressants are defined as agents that completely or partly suppress one or more factors in the immunosystem.
This group comprises immunosuppressants excl. corticosteroids.
|The DDDs are mainly based on prophylaxis of allograft transplant rejection.|
The DDD for muromonab-CD3 is based on combination therapy in acute allograft rejection.
The DDD for efalizumab is based on the treatment of plaque psoriasis.
The DDDs for etanercept, infliximab, leflunomide, anakinra and adalimumab are based on the treatment of rheumatoid arthritis.
The DDD for thalidomide is based on the treatment of erythema nodosum leprosum.
The DDD for lenalidomide is based on the treatment of myelodysplastic syndromes.
L04AX Other immunosuppressants
Oral formulations and prefilled syringe/pen of methotrexate are classified in this group. Parenteral formulations used in cancer are classified in L01BA01.
|The DDD for pomalidomide is based on the starting dose.|
Last updated: 2016-12-19